Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum

Support a global approach to the challenge of HIV vaccine R&D that transcends individual funders, countries, researchers, and civil society Enterprise in 2013: An Important Role to play

4 Make best use of existing resources Engage new funders and resources Promote more efficient, faster ways for researchers and funders to share findings and avoid duplication of efforts Convene scientific community to share and discuss information & data Identify priority issues where collective effort is most effective Engage current and new partners in the field Identify new, unmet priority areas where additional resources are needed Enterprise in 2012: An Important Role to Play Support a global approach to the challenge of HIV vaccine R&D that transcends individual funders, countries, researchers, and civil society Coordination Collaboration Resource Optimization Knowledge Sharing Share info on strategies, current & planned activities, and budget

6

7 Priority Areas Identified  Clinical trial site capacity  Faster access to GMP product  Access to and comparability of multiple adjuvants  Industry expertise  Advancement criteria for efficacy trials  Tools to help funders’ maintain funding

Potential advantages Involvement in planning Shared vision and work ethic Active involvement in projects and decision-making Investment in local infrastructure and capacity building Equal partnerships Shared responsibility Cautions from a seasoned collaborator Never collaborate for it’s own sake The collaboration must have benefits that are greater than the costs Don’s force collaboration